Please use this identifier to cite or link to this item:
|Title:||Assessment of amyloid β in pathologically confirmed frontotemporal dementia syndromes|
|Authors:||Tan, Rachel H;Kril, Jillian J;Yang, Yue;Tom, Nicole;Hodges, John R;Villemagne, Victor L;Rowe, Christopher C;Leyton, Cristian E;Kwok, John BJ;Ittner, Lars M;Halliday, Glenda M|
|Citation:||Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring 2017; 9: 10-20|
|Abstract:||INTRODUCTION: The diagnostic utility of in vivo amyloid β (Aβ) imaging to aid in the clinical distinction between frontotemporal dementia (FTD) and Alzheimer's disease remains unclear without data on the prevalence and severity of Aβ in pathologically confirmed FTD syndromes. METHODS: Aβ was assessed in 98 autopsy-confirmed FTD and 36 control cases, and the pathological accuracy of 11C-Pittsburgh compound B (PiB)-positron emission tomography imaging was assessed in a subset of FTD cases (n = 15). RESULTS: Aβ was identified in a similar proportion of FTD syndromes and age-matched controls and increases with age. Alzheimer's disease pathology was identified in all cases with high PiB retention and in one case with low PiB retention. We further demonstrate a strong regional correlation between volume fraction of histological Aβ with PiB standard uptake value ratio scaled to the white matter. DISCUSSION: The present study provides a pathologic reference to assist in the interpretation of in vivo assessments in FTD syndromes.|
|Subjects:||Frontotemporal dementia syndromes|
C-Pittsburgh compound B
|Appears in Collections:||Journal articles|
Files in This Item:
There are no files associated with this item.
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.